<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540787</url>
  </required_header>
  <id_info>
    <org_study_id>A4</org_study_id>
    <nct_id>NCT00540787</nct_id>
  </id_info>
  <brief_title>A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic
      drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of Atrial Fibrillation</measure>
    <time_frame>One year</time_frame>
    <description>To compare the incidence of recurrence of Atrial Fibrillation in the two groups over a follow-up period of one year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ablation and drug treatment</measure>
    <time_frame>One year</time_frame>
    <description>Evaluation of:
the functional state of the 2 groups of patients in terms of quality of life
the efficacy of the subgroup receiving amiodarone as compared to curative ablation
the incidence of secondary effects of both approaches
the rate of withdrawal from oral anticoagulation at 1 year after randomization
the effect of ablation for maintenance of sinus rhythm with previously ineffective drugs in case of failure of ablation strategy (after cross-over to medical treatment)
the assessment of Atrial fibrillation burden in both groups (using patient diaries and Holter Monitors)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Drug Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ThermoCool Radiofrequency Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiofrequency catheter used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation, antiarrhythmic drugs</intervention_name>
    <description>Patients receive either treatment.</description>
    <arm_group_label>Drug Treatment</arm_group_label>
    <arm_group_label>ThermoCool Radiofrequency Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs</intervention_name>
    <description>Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.</description>
    <arm_group_label>Drug Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ThermoCool Radiofrequency Catheter</intervention_name>
    <description>Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.</description>
    <arm_group_label>ThermoCool Radiofrequency Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Paroxysmal atrial fibrillation for at least 6 months with at least 2 symptomatic
             episodes (patient history) during the previous month

          -  Atrial fibrillation (patient history or echocardiogram documented) resistant to at
             least one antiarrhythmic drug of Class I or III

          -  Documentation of at least one episode of atrial fibrillation on 12-lead echocardiogram
             or Holter Monitor

        Exclusion Criteria:

          -  Contraindications to more than 2 antiarrhythmic drugs of different classes, or to oral
             anticoagulants

          -  History of any previous ablation for atrial fibrillation

          -  Intracardiac thrombus

          -  Atrial fibrillation due to reversible cause

          -  Pregnancy

          -  Contraindication to stopping oral anticoagulation (for example as a result of a
             mechanical cardiac valve)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Jais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Haut Lèvêque</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Ohio Cardiology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lèvêque</name>
      <address>
        <city>Pessac</city>
        <state>Paris</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>12111</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dofetilide</mesh_term>
    <mesh_term>Cifenline</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Sotalol</mesh_term>
    <mesh_term>Propafenone</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

